Sera Prognostics Inc Revenue Growth Rates (SERA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sera Prognostics Inc   (NASDAQ: SERA)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

SERA's Revenue Growth by Quarter and Year

Sera Prognostics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SERA/growth
https://api.csimarket.com/api/v1/companies/SERA/fundamentals
https://api.csimarket.com/api/v1/companies/SERA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
SERA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.04
2nd Quarter June 0.03
1st Quarter March 0.01
FY 0.08

SERAs Annual Revenue
Sera Prognostics Inc 's Revenue in the fiscal year 2025 $ 0.08 millions
Sera Prognostics Inc 's Revenue in the fiscal year 2024 $ 0.08 millions
Sera Prognostics Inc 's Revenue in the fiscal year 2023 $ 0.31 millions
Sera Prognostics Inc 's Revenue in the fiscal year 2022 $ 0.27 millions
Sera Prognostics Inc 's Revenue in the fiscal year 2021 $ 0.08 millions




SERA Revenue third quarter 2026 Y/Y Growth Comment
Sera Prognostics Inc achieved in the third quarter 2026, above Company average Revenue surge of 110% year on year, to $ 0.04 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 3 other companies have achieved higher Revenue growth. While Sera Prognostics Inc ' s Revenue doubling of 110% ranks overall at the positon no. 459 in the third quarter 2026.


SERA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 110 %
2nd Quarter June 50 %
1st Quarter March -75 %
FY   -

Financial Statements
Sera Prognostics Inc 's third quarter 2026 Revenue $ 0.04 millions SERA's Income Statement
Sera Prognostics Inc 's third quarter 2025 Revenue $ 0.02 millions Quarterly SERA's Income Statement


SERA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 40 %
2nd Quarter June 200 %
1st Quarter March 0 %
FY (Year on Year)   -


Back to SERA Growth rate Comparisons >> Back to SERA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #119
Overall #459

Revenue Y/Y Growth Statistics
High Average Low
360 % 67.5 % -100 %
(Sep 30 2022)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #119
Overall #459
Revenue Y/Y Growth Statistics
High Average Low
360 % 67.5 % -100 %
(Sep 30 2022)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Sera Prognostics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
180 % 17.48 % -100 %
(Dec 31 2020)  


SERA's III. Quarter Q/Q Revenue Comment
Sera Prognostics Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 40%, to $ 0.04 millions, from $0.03 millions in the second quarter.

Within Medical Laboratories industry Sera Prognostics Inc achieved highest sequential Revenue growth. While Sera Prognostics Inc 's Revenue growth quarter on quarter, overall rank is 87.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #33
Overall #87
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #33
Overall #87
Revenue Q/Q Growth Statistics
High Average Low
180 % 17.48 % -100 %
(Dec 31 2020)  


SERA's III. Quarter Q/Q Revenue Comment
Sera Prognostics Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 40%, to $ 0.04 millions, from $0.03 millions in the second quarter.

Within Medical Laboratories industry Sera Prognostics Inc achieved highest sequential Revenue growth. While Sera Prognostics Inc 's Revenue growth quarter on quarter, overall rank is 87.


Sera Prognostics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.07
Y / Y Revenue Growth (TTM) -35.19 %
Year on Year Revenue Growth Overall Ranking # 3575
Seqeuential Revenue Change (TTM) 22.81 %
Seq. Revenue Growth (TTM) Overall Ranking # 3065


Cumulative Revenue growth Comment
Sera Prognostics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Sera Prognostics Inc 's annual Revenue increase would be -35.19% year on year to $0 millions.

In the Healthcare sector 495 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3043 to 3575.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 496
Overall # 3575

Revenue TTM Y/Y Growth Statistics
High Average Low
227.14 %
 116.12 %
-50.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 417
S&P 500 # 3065
Cumulative Revenue growth Comment
Sera Prognostics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Sera Prognostics Inc 's annual Revenue drop would be -35.19% year on year to $0 millions.

In the Healthcare sector 495 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3043 to 3575.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 496
Overall # 3575

Revenue TTM Y/Y Growth Statistics
High Average Low
227.14 %
116.12 %
-50.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 417
S&P 500 # 3065




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SERA's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Neuraxis Inc 149.92%$ 149.922 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions


About Sera Prognostics Inc Revenue Growth Rates (SERA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sera Prognostics Inc (CIK 1534969).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001534969-26-000040
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sera Prognostics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.